NCT03876769 2026-03-13
CASSIOPEIA
Novartis
Phase 2 Active not recruiting
Clinical Trials
14 trialsNCT05460533 2026-02-04
A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL)
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT05633615 2026-02-02
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
SWOG Cancer Research Network
Phase 2 Recruiting
NCT03642626 2026-01-23
MT2017-45: CAR-T Cell Therapy for Heme Malignancies
Masonic Cancer Center, University of Minnesota
Phase 2 Active not recruiting
NCT03568461 2025-10-07
ELARA
Novartis
Phase 2 Completed
NCT04234061 2024-11-07
TARMAC
Peter MacCallum Cancer Centre, Australia
Phase 2 Active not recruiting
NCT03610724 2024-06-20
BIANCA
Novartis
Phase 2 Completed
NCT02445248 2024-04-18
JULIET
Novartis
Phase 2 Completed
NCT02435849 2024-02-13
ELIANA
Novartis
Phase 2 Completed
NCT04161118 2023-05-06
TIGER-CTL019
University of Cologne
Phase 2 Terminated
NCT04156659 2023-03-09
Study of Tisagenlecleucel in Chinese Pediatric and Young Adult Subjects With Relapsed or Refractory B-cell ALL
Novartis
Phase 2 Withdrawn
NCT04456023 2022-03-02
Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-cell Non-Hodgkin Lymphoma (DLBCL)
Novartis
Phase 2 Withdrawn
NCT02228096 2020-11-23
ENSIGN
Novartis
Phase 2 Completed
NCT02167360 2017-02-14
Study of Efficacy and Safety of CTL019 in Adult ALL Patients
Abramson Cancer Center at Penn Medicine
Phase 2 Withdrawn